QI
ABEO icon

QS Investors’s Abeona Therapeutics ABEO Stock Holding History

QS Investors’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$507K Hold
13,000
– – 0.01% 733
2021
Q1 		$611K Buy
13,000
+4,400
+51% +$242K 0.01% 714
2020
Q4 		$338K Buy
+8,600
New +$293K ﹤0.01% 939

Other funds holding ABEO

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

QS Investors's ABEO Position: Q2 2021 in Review

QS Investors held its Abeona Therapeutics (ABEO) position steady in Q2 2021 at 13,000 shares worth $507K. The position accounts for 0.01% of the portfolio, ranked #733.

QS Investors first reported a position in ABEO in Q4 2020 and has held it in 3 quarters since. The position peaked at $611K in Q1 2021. 70 funds tracked by Wall St. Rank hold ABEO as of Q2 2021.

  • QS Investors held 13,000 shares of Abeona Therapeutics worth $507K as of Q2 2021.
  • QS Investors left its Abeona Therapeutics share count unchanged in Q2 2021.
  • Abeona Therapeutics made up 0.01% of QS Investors's portfolio in Q2 2021, its #733 holding.
  • QS Investors first reported a position in Abeona Therapeutics in Q4 2020 and has held it in 3 quarters since.
  • QS Investors's Abeona Therapeutics position peaked at $611K in Q1 2021.
  • 70 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.